Sector: Commercial Services & Supplies - Services
BSE Code: 524414
NSE Symbol: NORRIS
ISIN: INE744C01029
Norris Medicines Q3 2025: Strong Revenue Growth & Profit Turnaround 📊 • Q3 2025 revenue: ₹326.66 lakhs, up from ₹110.60 lakhs in Q3 2024 • Q3 2025 profit before tax: ₹69.74 lakhs, compared to a loss of ₹28.17 lakhs in Q3 2024 • Nine-month loss before tax (ended Dec 31, 2025): ₹33.12 lakhs, reduce…
📊 Norris Medicines Ltd: BSE Closes Reclassification Application • BSE Limited closed the reclassification application (Case ID 223728) for Norris Medicines Limited on 12 February 2026. • Closure occurred due to non-payment of a disputed penalty. • Existing shareholder classification remains uncha…
📊 Norris Medicines Board Meeting: Q3 & 9M FY2026 Results on Feb 14 • Board meeting scheduled for February 14, 2026 at registered office in Ankleshwar, Gujarat • Will consider and approve Un-audited Financial Results for quarter and nine months ended December 31, 2025 • Limited Review Report to be…
Norris Medicines CFO Resigns Effective 2026 📅 - Mr. Iqubal Patel resigned as Chief Financial Officer (CFO) and Key Managerial Personnel - Resignation effective from February 03, 2026, after business hours - Resignation due to personal reasons - Company is in the process of appointing a new CFO - …
Norris Medicines Ltd Shares Key Compliance Update for Q4 2025 📋 - Compliance certificate submitted for quarter ending December 31, 2025, under SEBI Regulation 74(5). - Registrar and Transfer Agent Purva Sharegistry (India) Private Limited handled the process. - Securities for dematerialization we…
Norris Medicines Independent Director Steps Down 🚪 - Ms. Sathya Venkatachalam (DIN: 06970735) resigns as Independent Director of Norris Medicines Limited, effective December 12, 2025. - Resignation is due to personal reasons; no other material reasons cited. - Steps down from all company committe…
Norris Medicines Clears NAFDAC Audit with Zero Critical Findings ✅ - Successfully completed NAFDAC audit in Nigeria on December 9, 2025. - Zero critical observations reported during the review. - Audit covered quality systems, manufacturing practices, and compliance parameters.
Norris Medicines Ltd Wins Legal Appeal in Bombay High Court ⚖️ - Norris Medicines Ltd's Criminal Appeal No. 89 of 2020 was allowed by the Bombay High Court on 19 November 2025. - The appeal challenged an order requiring a deposit of ₹1,32,92,359 with 18% simple interest under the MPID Act. - The H…
Norris Medicines Q2 2025: Revenue Up, Losses Widen 📊💊 - Revenue: ₹200.04L in Q2 (Sep 2025) vs ₹145.66L in Q1 (Jun 2025) – 37% quarterly growth - Year-over-year: Q2 revenue up from ₹126.84L in Sep 2024 - Losses: Q2 loss at ₹-71.82L vs ₹-31.04L in Q1 and ₹-36.11L in Q2 2024 - Half-year loss: ₹-102…
📅 Norris Medicines Ltd Board Meeting: Key Updates on Nov 14 - Board Meeting scheduled for November 14, 2025, at Ankleshwar, Gujarat. - Agenda includes approval of Un-audited Financial Results for the quarter ended June 30, 2025. - Limited Review Report will also be reviewed. - Trading Window clos…
Norris Medicines Ltd Announces Key Auditor Appointments 📊 - Board of Directors approved M/s. Dhiren Y Parikh & Co. as Internal Auditors for FY 2025-2026. - M/s. Dhiren Y Parikh & Co. is based in Vadodara, Gujarat, specializing in audit, consulting, taxation, and corporate advisory. - M/s. HSPN As…
Norris Medicines Q1 2025: Revenue Doubles, Losses Persist 📊 - Revenue from operations: ₹145.66L (vs ₹72.49L same quarter last year) - Total income (net): ₹148.04L - Loss before tax: ₹31.04L - Loss after tax: ₹31.04L - No exceptional/extraordinary items - Single business segment (no segmental repo…
📅 Norris Medicines Board Meeting: Key Financial Review on Aug 14 - Board meeting scheduled for August 14, 2025, at Ankleshwar, Gujarat. - Agenda includes approval of Un-audited Financial Results for Q2 (ended June 30, 2025). - Trading Window closed since July 1, 2025, reopening 48 hours post-resu…